Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-07-15

Clinical Trial Update: Intrathecal Neostigmine for Prevention of PDPH [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating intrathecal neostigmine for prevention of post-dural puncture headache has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Neostigmine (neostigmine)

Snippet

Sponsor: Fayoum University Hospital | Conditions: Post-Dural Puncture Headache | Phase 4 | Status: COMPLETED